Why Nikkei 225 (JP225) rose 1.22%
Nikkei 225 (JP225) rose 1.22% on August 21, 2026 — Celltrion Japan autoimmune launch boosts Nikkei.
What happened
Celltrion, a Korean biopharma, launched SteQeyma IV (a copycat autoimmune drug) in Japan, marking an expansion of its local presence and signaling a new product revenue stream in the region.
Why it moved
A successful Japan pharma launch lifts sentiment around Korean healthcare export competitiveness and bilateral trade momentum, supporting the Nikkei as a regional bellwether; this adds marginal tailwind to the Japan…
Why it matters
The Japan (Yen & Equities) theme is currently caught in BoJ tightening — today's move reflects modest equity strength overcoming carry-unwind headwinds, with Celltrion's Japan expansion adding positive trade-flow…
What would break the thesis
If SteQeyma IV uptake stalls due to reimbursement delays or clinical headwinds, or if broader Japan export momentum cools, the pharma trade narrative weakens and the Nikkei loses this support.